Regis Technologies, Inc., a Chicago-based CMO focused on small molecule active pharmaceutical ingredients (API), partners with pharmaceutical companies to expedite drugs to the clinic and ultimately to the market. We offer synthesis, analytical and separation services to advance your API from initial process development to final validation and commercial manufacturing. Let our veteran project managers successfully guide your molecule through the IND and NDA processes.
Regis Technologies operates an FDA inspected cGMP facility with about 36,000 square feet of production space housing eight reactor suites from 25 to 500 gallons. Recently added, Regis’ Potent Compound Suite (PCS) is qualified and ready for projects. The PCS addition allows Regis to serve the oncology market by providing for small molecule cGMP manufacturing of potent compounds up to about one kilogram per batch.
Partner with the proven provider since 1956.